Apimeds Pharmaceuticals US (APUS) EPS (Basic) (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly EPS (Basic) came in at -$6.69 in Q4 2025, down 1277.97% YoY from $0.57 in Q4 2024, and down 369.1% on a QoQ basis from -$1.43 in Q3 2025.
Apimeds Pharmaceuticals US (APUS) EPS (Basic) (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 2 years of EPS (Basic) data on file, last reported at -$6.69 in Q4 2025.
- Quarterly EPS (Basic) fell 1277.97% year-over-year to -$6.69 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$11.17 (down 503.57% YoY) and the FY2025 annual result came in at -$13.28, down 334.93% from the prior year.
- EPS (Basic) retreated to -$6.69 in Q4 2025, from -$1.43 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$0.38 in Q1 2024 to a low of -$6.69 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -0.49 |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 2.07 |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 0.45 |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 7.82 |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | -0.10 |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 1.43 |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 0.11 |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Apimeds Pharmaceuticals US | 7.20 Mn | 7.20 Mn | - | -5.53 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.69 |
| Sep 30, 2025 | -1.43 |
| Jun 30, 2025 | -2.58 |
| Mar 31, 2025 | -0.51 |
| Dec 31, 2024 | -0.49 |
| Sep 30, 2024 | -0.42 |
| Jun 30, 2024 | -0.57 |
| Mar 31, 2024 | -0.38 |